Abstract
Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have